908 Devices Inc.

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, MASS is priced at $6.74, while BSX-PA trades at $122.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, MASS's ROE is +0.13%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, MASS is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check BSX-PA's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, ABT has a market cap of 158.4B. Regarding current trading prices, MASS is priced at $6.74, while ABT trades at $91.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas ABT's P/E ratio is 25.53. In terms of profitability, MASS's ROE is +0.13%, compared to ABT's ROE of +0.12%. Regarding short-term risk, MASS is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check ABT's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, SYK has a market cap of 125.4B. Regarding current trading prices, MASS is priced at $6.74, while SYK trades at $327.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas SYK's P/E ratio is 38.94. In terms of profitability, MASS's ROE is +0.13%, compared to SYK's ROE of +0.15%. Regarding short-term risk, MASS is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check SYK's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, MDT has a market cap of 107B. Regarding current trading prices, MASS is priced at $6.74, while MDT trades at $83.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas MDT's P/E ratio is 23.28. In terms of profitability, MASS's ROE is +0.13%, compared to MDT's ROE of +0.10%. Regarding short-term risk, MASS is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check MDT's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, BSX has a market cap of 92.2B. Regarding current trading prices, MASS is priced at $6.74, while BSX trades at $62.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas BSX's P/E ratio is 25.97. In terms of profitability, MASS's ROE is +0.13%, compared to BSX's ROE of +0.15%. Regarding short-term risk, MASS is less volatile compared to BSX. This indicates potentially lower risk in terms of short-term price fluctuations for MASS.Check BSX's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, EW has a market cap of 48.6B. Regarding current trading prices, MASS is priced at $6.74, while EW trades at $84.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas EW's P/E ratio is 46.52. In terms of profitability, MASS's ROE is +0.13%, compared to EW's ROE of +0.10%. Regarding short-term risk, MASS is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check EW's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, BRKRP has a market cap of 44.2B. Regarding current trading prices, MASS is priced at $6.74, while BRKRP trades at $292.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas BRKRP's P/E ratio is N/A. In terms of profitability, MASS's ROE is +0.13%, compared to BRKRP's ROE of -0.00%. Regarding short-term risk, MASS is more volatile compared to BRKRP. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check BRKRP's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, PHG has a market cap of 26.3B. Regarding current trading prices, MASS is priced at $6.74, while PHG trades at $27.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas PHG's P/E ratio is 25.20. In terms of profitability, MASS's ROE is +0.13%, compared to PHG's ROE of +0.08%. Regarding short-term risk, MASS is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check PHG's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, DXCM has a market cap of 23.8B. Regarding current trading prices, MASS is priced at $6.74, while DXCM trades at $61.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas DXCM's P/E ratio is 29.46. In terms of profitability, MASS's ROE is +0.13%, compared to DXCM's ROE of +0.32%. Regarding short-term risk, MASS is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check DXCM's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, STE has a market cap of 21.8B. Regarding current trading prices, MASS is priced at $6.74, while STE trades at $221.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas STE's P/E ratio is 30.89. In terms of profitability, MASS's ROE is +0.13%, compared to STE's ROE of +0.10%. Regarding short-term risk, MASS is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check STE's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, ZBH has a market cap of 17.9B. Regarding current trading prices, MASS is priced at $6.74, while ZBH trades at $91.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas ZBH's P/E ratio is 26.45. In terms of profitability, MASS's ROE is +0.13%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, MASS is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check ZBH's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, MASS is priced at $6.74, while ABMD trades at $381.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas ABMD's P/E ratio is 65.36. In terms of profitability, MASS's ROE is +0.13%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, MASS is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check ABMD's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, ALGN has a market cap of 13.6B. Regarding current trading prices, MASS is priced at $6.74, while ALGN trades at $189.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas ALGN's P/E ratio is 33.62. In terms of profitability, MASS's ROE is +0.13%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, MASS is more volatile compared to ALGN. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check ALGN's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, SNN has a market cap of 13.5B. Regarding current trading prices, MASS is priced at $6.74, while SNN trades at $31.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas SNN's P/E ratio is 22.07. In terms of profitability, MASS's ROE is +0.13%, compared to SNN's ROE of +0.12%. Regarding short-term risk, MASS is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check SNN's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, PODD has a market cap of 13.3B. Regarding current trading prices, MASS is priced at $6.74, while PODD trades at $189.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas PODD's P/E ratio is 54.47. In terms of profitability, MASS's ROE is +0.13%, compared to PODD's ROE of +0.17%. Regarding short-term risk, MASS is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check PODD's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, PEN has a market cap of 12.9B. Regarding current trading prices, MASS is priced at $6.74, while PEN trades at $329.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas PEN's P/E ratio is 72.78. In terms of profitability, MASS's ROE is +0.13%, compared to PEN's ROE of +0.13%. Regarding short-term risk, MASS is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check PEN's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, GMED has a market cap of 12.8B. Regarding current trading prices, MASS is priced at $6.74, while GMED trades at $94.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas GMED's P/E ratio is 24.20. In terms of profitability, MASS's ROE is +0.13%, compared to GMED's ROE of +0.12%. Regarding short-term risk, MASS is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check GMED's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, MASS is priced at $6.74, while SWAV trades at $334.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas SWAV's P/E ratio is 78.76. In terms of profitability, MASS's ROE is +0.13%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, MASS is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check SWAV's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, BIO-B has a market cap of 8.1B. Regarding current trading prices, MASS is priced at $6.74, while BIO-B trades at $299.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas BIO-B's P/E ratio is 10.75. In terms of profitability, MASS's ROE is +0.13%, compared to BIO-B's ROE of +0.11%. Regarding short-term risk, MASS is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check BIO-B's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, BIO has a market cap of 7.8B. Regarding current trading prices, MASS is priced at $6.74, while BIO trades at $287.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas BIO's P/E ratio is 10.33. In terms of profitability, MASS's ROE is +0.13%, compared to BIO's ROE of +0.11%. Regarding short-term risk, MASS is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check BIO's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, GKOS has a market cap of 7.1B. Regarding current trading prices, MASS is priced at $6.74, while GKOS trades at $121.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas GKOS's P/E ratio is -37.05. In terms of profitability, MASS's ROE is +0.13%, compared to GKOS's ROE of -0.25%. Regarding short-term risk, MASS is more volatile compared to GKOS. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check GKOS's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, BRKR has a market cap of 5.6B. Regarding current trading prices, MASS is priced at $6.74, while BRKR trades at $36.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas BRKR's P/E ratio is -243.63. In terms of profitability, MASS's ROE is +0.13%, compared to BRKR's ROE of -0.00%. Regarding short-term risk, MASS is more volatile compared to BRKR. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check BRKR's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, MASS is priced at $6.74, while NARI trades at $79.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas NARI's P/E ratio is -59.24. In terms of profitability, MASS's ROE is +0.13%, compared to NARI's ROE of -0.00%. Regarding short-term risk, MASS is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check NARI's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, IRTC has a market cap of 4B. Regarding current trading prices, MASS is priced at $6.74, while IRTC trades at $122.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas IRTC's P/E ratio is -88.02. In terms of profitability, MASS's ROE is +0.13%, compared to IRTC's ROE of -0.38%. Regarding short-term risk, MASS is more volatile compared to IRTC. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check IRTC's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, TMDX has a market cap of 3.8B. Regarding current trading prices, MASS is priced at $6.74, while TMDX trades at $110.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas TMDX's P/E ratio is 22.81. In terms of profitability, MASS's ROE is +0.13%, compared to TMDX's ROE of +0.54%. Regarding short-term risk, MASS is more volatile compared to TMDX. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check TMDX's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, MASS is priced at $6.74, while AXNX trades at $70.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas AXNX's P/E ratio is -709.80. In terms of profitability, MASS's ROE is +0.13%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, MASS is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check AXNX's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, LIVN has a market cap of 3.5B. Regarding current trading prices, MASS is priced at $6.74, while LIVN trades at $64.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas LIVN's P/E ratio is -14.43. In terms of profitability, MASS's ROE is +0.13%, compared to LIVN's ROE of -0.21%. Regarding short-term risk, MASS is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check LIVN's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, ITGR has a market cap of 3B. Regarding current trading prices, MASS is priced at $6.74, while ITGR trades at $86.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas ITGR's P/E ratio is 29.76. In terms of profitability, MASS's ROE is +0.13%, compared to ITGR's ROE of +0.06%. Regarding short-term risk, MASS is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check ITGR's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, MASS is priced at $6.74, while NUVA trades at $39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas NUVA's P/E ratio is 75.00. In terms of profitability, MASS's ROE is +0.13%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, MASS is more volatile compared to NUVA. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check NUVA's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, AXGN has a market cap of 2B. Regarding current trading prices, MASS is priced at $6.74, while AXGN trades at $39.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas AXGN's P/E ratio is -115.44. In terms of profitability, MASS's ROE is +0.13%, compared to AXGN's ROE of -0.13%. Regarding short-term risk, MASS is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for MASS.Check AXGN's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, ESTA has a market cap of 1.9B. Regarding current trading prices, MASS is priced at $6.74, while ESTA trades at $66.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas ESTA's P/E ratio is -38.53. In terms of profitability, MASS's ROE is +0.13%, compared to ESTA's ROE of -2.02%. Regarding short-term risk, MASS is more volatile compared to ESTA. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check ESTA's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, AORT has a market cap of 1.8B. Regarding current trading prices, MASS is priced at $6.74, while AORT trades at $37.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas AORT's P/E ratio is 188.90. In terms of profitability, MASS's ROE is +0.13%, compared to AORT's ROE of +0.02%. Regarding short-term risk, MASS is more volatile compared to AORT. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check AORT's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, AHCO has a market cap of 1.7B. Regarding current trading prices, MASS is priced at $6.74, while AHCO trades at $12.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas AHCO's P/E ratio is -24.62. In terms of profitability, MASS's ROE is +0.13%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, MASS is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check AHCO's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, ATEC has a market cap of 1.6B. Regarding current trading prices, MASS is priced at $6.74, while ATEC trades at $10.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas ATEC's P/E ratio is -11.35. In terms of profitability, MASS's ROE is +0.13%, compared to ATEC's ROE of -17.60%. Regarding short-term risk, MASS is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for MASS.Check ATEC's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, INSP has a market cap of 1.6B. Regarding current trading prices, MASS is priced at $6.74, while INSP trades at $56.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas INSP's P/E ratio is 11.51. In terms of profitability, MASS's ROE is +0.13%, compared to INSP's ROE of +0.21%. Regarding short-term risk, MASS is more volatile compared to INSP. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check INSP's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, UFPT has a market cap of 1.5B. Regarding current trading prices, MASS is priced at $6.74, while UFPT trades at $200.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas UFPT's P/E ratio is 22.84. In terms of profitability, MASS's ROE is +0.13%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, MASS is more volatile compared to UFPT. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check UFPT's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, TNDM has a market cap of 1.4B. Regarding current trading prices, MASS is priced at $6.74, while TNDM trades at $20.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas TNDM's P/E ratio is -6.70. In terms of profitability, MASS's ROE is +0.13%, compared to TNDM's ROE of -1.42%. Regarding short-term risk, MASS is more volatile compared to TNDM. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check TNDM's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, PRCT has a market cap of 1.4B. Regarding current trading prices, MASS is priced at $6.74, while PRCT trades at $24.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas PRCT's P/E ratio is -14.16. In terms of profitability, MASS's ROE is +0.13%, compared to PRCT's ROE of -0.25%. Regarding short-term risk, MASS is more volatile compared to PRCT. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check PRCT's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, BFLY has a market cap of 1.4B. Regarding current trading prices, MASS is priced at $6.74, while BFLY trades at $5.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas BFLY's P/E ratio is -17.21. In terms of profitability, MASS's ROE is +0.13%, compared to BFLY's ROE of -0.35%. Regarding short-term risk, MASS is more volatile compared to BFLY. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check BFLY's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, PMI has a market cap of 1.3B. Regarding current trading prices, MASS is priced at $6.74, while PMI trades at $0.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas PMI's P/E ratio is -1.13. In terms of profitability, MASS's ROE is +0.13%, compared to PMI's ROE of +2.17%. Regarding short-term risk, MASS is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for MASS.Check PMI's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, MASS is priced at $6.74, while HSKA trades at $119.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas HSKA's P/E ratio is -62.49. In terms of profitability, MASS's ROE is +0.13%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, MASS is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check HSKA's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, CNMD has a market cap of 1.2B. Regarding current trading prices, MASS is priced at $6.74, while CNMD trades at $38.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas CNMD's P/E ratio is 25.38. In terms of profitability, MASS's ROE is +0.13%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, MASS is more volatile compared to CNMD. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check CNMD's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, MASS is priced at $6.74, while AVNS trades at $24.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas AVNS's P/E ratio is -15.73. In terms of profitability, MASS's ROE is +0.13%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, MASS is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check AVNS's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, MASS is priced at $6.74, while IRMD trades at $88.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas IRMD's P/E ratio is 52.79. In terms of profitability, MASS's ROE is +0.13%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, MASS is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check IRMD's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, MASS is priced at $6.74, while SILK trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas SILK's P/E ratio is -18.96. In terms of profitability, MASS's ROE is +0.13%, compared to SILK's ROE of -0.35%. Regarding short-term risk, MASS is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check SILK's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, MASS is priced at $6.74, while FNA trades at $13.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas FNA's P/E ratio is -19.83. In terms of profitability, MASS's ROE is +0.13%, compared to FNA's ROE of -0.35%. Regarding short-term risk, MASS is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check FNA's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, LMRI has a market cap of 922.7M. Regarding current trading prices, MASS is priced at $6.74, while LMRI trades at $9.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas LMRI's P/E ratio is -14.55. In terms of profitability, MASS's ROE is +0.13%, compared to LMRI's ROE of -0.18%. Regarding short-term risk, MASS is less volatile compared to LMRI. This indicates potentially lower risk in terms of short-term price fluctuations for MASS.Check LMRI's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, INMD has a market cap of 912.4M. Regarding current trading prices, MASS is priced at $6.74, while INMD trades at $14.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas INMD's P/E ratio is 10.07. In terms of profitability, MASS's ROE is +0.13%, compared to INMD's ROE of +0.15%. Regarding short-term risk, MASS is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check INMD's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, SSII has a market cap of 872.6M. Regarding current trading prices, MASS is priced at $6.74, while SSII trades at $4.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas SSII's P/E ratio is -72.67. In terms of profitability, MASS's ROE is +0.13%, compared to SSII's ROE of -0.30%. Regarding short-term risk, MASS is more volatile compared to SSII. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check SSII's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, MASS is priced at $6.74, while CSII trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas CSII's P/E ratio is -20.83. In terms of profitability, MASS's ROE is +0.13%, compared to CSII's ROE of -0.14%. Regarding short-term risk, MASS is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check CSII's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, IART has a market cap of 823.8M. Regarding current trading prices, MASS is priced at $6.74, while IART trades at $10.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas IART's P/E ratio is -1.57. In terms of profitability, MASS's ROE is +0.13%, compared to IART's ROE of -0.44%. Regarding short-term risk, MASS is more volatile compared to IART. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check IART's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, CBLL has a market cap of 797.2M. Regarding current trading prices, MASS is priced at $6.74, while CBLL trades at $21.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas CBLL's P/E ratio is -14.51. In terms of profitability, MASS's ROE is +0.13%, compared to CBLL's ROE of -0.32%. Regarding short-term risk, MASS is more volatile compared to CBLL. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check CBLL's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, MASS is priced at $6.74, while CRY trades at $17.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas CRY's P/E ratio is 425.71. In terms of profitability, MASS's ROE is +0.13%, compared to CRY's ROE of +0.02%. Regarding short-term risk, MASS is more volatile compared to CRY. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check CRY's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, BVS has a market cap of 679.7M. Regarding current trading prices, MASS is priced at $6.74, while BVS trades at $10.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas BVS's P/E ratio is 30.58. In terms of profitability, MASS's ROE is +0.13%, compared to BVS's ROE of +0.14%. Regarding short-term risk, MASS is more volatile compared to BVS. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check BVS's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, BWAY has a market cap of 642.1M. Regarding current trading prices, MASS is priced at $6.74, while BWAY trades at $16.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas BWAY's P/E ratio is 90.94. In terms of profitability, MASS's ROE is +0.13%, compared to BWAY's ROE of +0.11%. Regarding short-term risk, MASS is more volatile compared to BWAY. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check BWAY's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, MASS is priced at $6.74, while SRDX trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas SRDX's P/E ratio is -34.66. In terms of profitability, MASS's ROE is +0.13%, compared to SRDX's ROE of -0.13%. Regarding short-term risk, MASS is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check SRDX's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, SIBN has a market cap of 597.1M. Regarding current trading prices, MASS is priced at $6.74, while SIBN trades at $13.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas SIBN's P/E ratio is -30.73. In terms of profitability, MASS's ROE is +0.13%, compared to SIBN's ROE of -0.11%. Regarding short-term risk, MASS is less volatile compared to SIBN. This indicates potentially lower risk in terms of short-term price fluctuations for MASS.Check SIBN's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, MASS is priced at $6.74, while APEN trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas APEN's P/E ratio is -9.43. In terms of profitability, MASS's ROE is +0.13%, compared to APEN's ROE of -0.85%. Regarding short-term risk, MASS is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check APEN's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, TCMD has a market cap of 570.4M. Regarding current trading prices, MASS is priced at $6.74, while TCMD trades at $25.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas TCMD's P/E ratio is 30.57. In terms of profitability, MASS's ROE is +0.13%, compared to TCMD's ROE of +0.09%. Regarding short-term risk, MASS is less volatile compared to TCMD. This indicates potentially lower risk in terms of short-term price fluctuations for MASS.Check TCMD's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, CTKB has a market cap of 565.6M. Regarding current trading prices, MASS is priced at $6.74, while CTKB trades at $4.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas CTKB's P/E ratio is -8.46. In terms of profitability, MASS's ROE is +0.13%, compared to CTKB's ROE of -0.18%. Regarding short-term risk, MASS is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for MASS.Check CTKB's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, NPCE has a market cap of 565.6M. Regarding current trading prices, MASS is priced at $6.74, while NPCE trades at $16.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas NPCE's P/E ratio is -25.45. In terms of profitability, MASS's ROE is +0.13%, compared to NPCE's ROE of -1.06%. Regarding short-term risk, MASS is more volatile compared to NPCE. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check NPCE's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, MASS is priced at $6.74, while ZIMV trades at $18.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, MASS's ROE is +0.13%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, MASS is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check ZIMV's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, VREX has a market cap of 525.3M. Regarding current trading prices, MASS is priced at $6.74, while VREX trades at $12.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas VREX's P/E ratio is -7.64. In terms of profitability, MASS's ROE is +0.13%, compared to VREX's ROE of -0.14%. Regarding short-term risk, MASS is more volatile compared to VREX. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check VREX's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, OFIX has a market cap of 495.8M. Regarding current trading prices, MASS is priced at $6.74, while OFIX trades at $12.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas OFIX's P/E ratio is -5.30. In terms of profitability, MASS's ROE is +0.13%, compared to OFIX's ROE of -0.20%. Regarding short-term risk, MASS is more volatile compared to OFIX. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check OFIX's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, PACB has a market cap of 471.1M. Regarding current trading prices, MASS is priced at $6.74, while PACB trades at $1.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas PACB's P/E ratio is -0.86. In terms of profitability, MASS's ROE is +0.13%, compared to PACB's ROE of -11.23%. Regarding short-term risk, MASS is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for MASS.Check PACB's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, KIDS has a market cap of 409.3M. Regarding current trading prices, MASS is priced at $6.74, while KIDS trades at $16.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas KIDS's P/E ratio is -9.58. In terms of profitability, MASS's ROE is +0.13%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, MASS is more volatile compared to KIDS. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check KIDS's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, CERS has a market cap of 380.5M. Regarding current trading prices, MASS is priced at $6.74, while CERS trades at $1.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas CERS's P/E ratio is -24.75. In terms of profitability, MASS's ROE is +0.13%, compared to CERS's ROE of -0.26%. Regarding short-term risk, MASS is more volatile compared to CERS. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check CERS's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, DCTH has a market cap of 376.6M. Regarding current trading prices, MASS is priced at $6.74, while DCTH trades at $10.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas DCTH's P/E ratio is 154.86. In terms of profitability, MASS's ROE is +0.13%, compared to DCTH's ROE of +0.03%. Regarding short-term risk, MASS is more volatile compared to DCTH. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check DCTH's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, VMD has a market cap of 372.9M. Regarding current trading prices, MASS is priced at $6.74, while VMD trades at $9.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas VMD's P/E ratio is 26.11. In terms of profitability, MASS's ROE is +0.13%, compared to VMD's ROE of +0.11%. Regarding short-term risk, MASS is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check VMD's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, LAB has a market cap of 350.9M. Regarding current trading prices, MASS is priced at $6.74, while LAB trades at $0.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas LAB's P/E ratio is -6.00. In terms of profitability, MASS's ROE is +0.13%, compared to LAB's ROE of -0.18%. Regarding short-term risk, MASS is more volatile compared to LAB. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check LAB's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, CLPT has a market cap of 349.4M. Regarding current trading prices, MASS is priced at $6.74, while CLPT trades at $11.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas CLPT's P/E ratio is -13.09. In terms of profitability, MASS's ROE is +0.13%, compared to CLPT's ROE of -1.22%. Regarding short-term risk, MASS is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for MASS.Check CLPT's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, CATX has a market cap of 333.3M. Regarding current trading prices, MASS is priced at $6.74, while CATX trades at $4.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas CATX's P/E ratio is -3.21. In terms of profitability, MASS's ROE is +0.13%, compared to CATX's ROE of -0.41%. Regarding short-term risk, MASS is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for MASS.Check CATX's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, MASS is priced at $6.74, while SMLR trades at $20.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas SMLR's P/E ratio is 3.92. In terms of profitability, MASS's ROE is +0.13%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, MASS is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check SMLR's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, RXST has a market cap of 299.2M. Regarding current trading prices, MASS is priced at $6.74, while RXST trades at $7.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas RXST's P/E ratio is -7.63. In terms of profitability, MASS's ROE is +0.13%, compared to RXST's ROE of -0.14%. Regarding short-term risk, MASS is more volatile compared to RXST. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check RXST's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, SENS has a market cap of 294.7M. Regarding current trading prices, MASS is priced at $6.74, while SENS trades at $7.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas SENS's P/E ratio is -4.25. In terms of profitability, MASS's ROE is +0.13%, compared to SENS's ROE of -1.04%. Regarding short-term risk, MASS is more volatile compared to SENS. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check SENS's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, MASS is priced at $6.74, while MGRM trades at $6.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas MGRM's P/E ratio is -11.11. In terms of profitability, MASS's ROE is +0.13%, compared to MGRM's ROE of -1.11%. Regarding short-term risk, MASS is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check MGRM's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, SGHT has a market cap of 235.5M. Regarding current trading prices, MASS is priced at $6.74, while SGHT trades at $4.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas SGHT's P/E ratio is -5.89. In terms of profitability, MASS's ROE is +0.13%, compared to SGHT's ROE of -0.56%. Regarding short-term risk, MASS is more volatile compared to SGHT. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check SGHT's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, MASS is priced at $6.74, while NVRO trades at $5.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas NVRO's P/E ratio is -1.91. In terms of profitability, MASS's ROE is +0.13%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, MASS is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check NVRO's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, ANIK has a market cap of 221.7M. Regarding current trading prices, MASS is priced at $6.74, while ANIK trades at $15.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas ANIK's P/E ratio is -21.96. In terms of profitability, MASS's ROE is +0.13%, compared to ANIK's ROE of -0.07%. Regarding short-term risk, MASS is more volatile compared to ANIK. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check ANIK's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, ELMD has a market cap of 220.1M. Regarding current trading prices, MASS is priced at $6.74, while ELMD trades at $26.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas ELMD's P/E ratio is 25.62. In terms of profitability, MASS's ROE is +0.13%, compared to ELMD's ROE of +0.20%. Regarding short-term risk, MASS is more volatile compared to ELMD. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check ELMD's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, PROF has a market cap of 211.5M. Regarding current trading prices, MASS is priced at $6.74, while PROF trades at $6.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas PROF's P/E ratio is -4.96. In terms of profitability, MASS's ROE is +0.13%, compared to PROF's ROE of -0.80%. Regarding short-term risk, MASS is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for MASS.Check PROF's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, EYES has a market cap of 210M. Regarding current trading prices, MASS is priced at $6.74, while EYES trades at $4.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas EYES's P/E ratio is N/A. In terms of profitability, MASS's ROE is +0.13%, compared to EYES's ROE of -3.17%. Regarding short-term risk, MASS is more volatile compared to EYES. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check EYES's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, AVR has a market cap of 205.3M. Regarding current trading prices, MASS is priced at $6.74, while AVR trades at $5.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas AVR's P/E ratio is -2.19. In terms of profitability, MASS's ROE is +0.13%, compared to AVR's ROE of -5.28%. Regarding short-term risk, MASS is more volatile compared to AVR. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check AVR's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, CVRX has a market cap of 203.1M. Regarding current trading prices, MASS is priced at $6.74, while CVRX trades at $7.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas CVRX's P/E ratio is -3.78. In terms of profitability, MASS's ROE is +0.13%, compared to CVRX's ROE of -0.99%. Regarding short-term risk, MASS is more volatile compared to CVRX. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check CVRX's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, INGN has a market cap of 192M. Regarding current trading prices, MASS is priced at $6.74, while INGN trades at $7.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas INGN's P/E ratio is -8.20. In terms of profitability, MASS's ROE is +0.13%, compared to INGN's ROE of -0.12%. Regarding short-term risk, MASS is more volatile compared to INGN. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check INGN's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, MASS is priced at $6.74, while BSGM trades at $6.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas BSGM's P/E ratio is -5.81. In terms of profitability, MASS's ROE is +0.13%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, MASS is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for MASS.Check BSGM's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, MASS is priced at $6.74, while MDGS trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas MDGS's P/E ratio is -0.27. In terms of profitability, MASS's ROE is +0.13%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, MASS is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for MASS.Check MDGS's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, QTI has a market cap of 178.3M. Regarding current trading prices, MASS is priced at $6.74, while QTI trades at $6.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas QTI's P/E ratio is -3.27. In terms of profitability, MASS's ROE is +0.13%, compared to QTI's ROE of +3.64%. Regarding short-term risk, MASS is more volatile compared to QTI. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check QTI's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, TLSI has a market cap of 175.9M. Regarding current trading prices, MASS is priced at $6.74, while TLSI trades at $4.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas TLSI's P/E ratio is -2.52. In terms of profitability, MASS's ROE is +0.13%, compared to TLSI's ROE of +1.37%. Regarding short-term risk, MASS is more volatile compared to TLSI. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check TLSI's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, MASS is priced at $6.74, while QIPT trades at $3.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas QIPT's P/E ratio is -15.87. In terms of profitability, MASS's ROE is +0.13%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, MASS is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check QIPT's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, SNWV has a market cap of 160.7M. Regarding current trading prices, MASS is priced at $6.74, while SNWV trades at $18.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas SNWV's P/E ratio is 45.61. In terms of profitability, MASS's ROE is +0.13%, compared to SNWV's ROE of -1.42%. Regarding short-term risk, MASS is more volatile compared to SNWV. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check SNWV's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, APYX has a market cap of 155.6M. Regarding current trading prices, MASS is priced at $6.74, while APYX trades at $3.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas APYX's P/E ratio is -13.78. In terms of profitability, MASS's ROE is +0.13%, compared to APYX's ROE of -1.18%. Regarding short-term risk, MASS is more volatile compared to APYX. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check APYX's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, QTRX has a market cap of 154M. Regarding current trading prices, MASS is priced at $6.74, while QTRX trades at $3.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas QTRX's P/E ratio is -1.31. In terms of profitability, MASS's ROE is +0.13%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, MASS is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for MASS.Check QTRX's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, TMCI has a market cap of 128.3M. Regarding current trading prices, MASS is priced at $6.74, while TMCI trades at $1.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas TMCI's P/E ratio is -2.13. In terms of profitability, MASS's ROE is +0.13%, compared to TMCI's ROE of -0.62%. Regarding short-term risk, MASS is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for MASS.Check TMCI's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, EDAP has a market cap of 121.1M. Regarding current trading prices, MASS is priced at $6.74, while EDAP trades at $3.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas EDAP's P/E ratio is -4.14. In terms of profitability, MASS's ROE is +0.13%, compared to EDAP's ROE of -1.12%. Regarding short-term risk, MASS is more volatile compared to EDAP. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check EDAP's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, NNOX has a market cap of 120.7M. Regarding current trading prices, MASS is priced at $6.74, while NNOX trades at $1.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas NNOX's P/E ratio is -1.50. In terms of profitability, MASS's ROE is +0.13%, compared to NNOX's ROE of -0.47%. Regarding short-term risk, MASS is less volatile compared to NNOX. This indicates potentially lower risk in terms of short-term price fluctuations for MASS.Check NNOX's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, FONR has a market cap of 116.2M. Regarding current trading prices, MASS is priced at $6.74, while FONR trades at $18.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas FONR's P/E ratio is 16.37. In terms of profitability, MASS's ROE is +0.13%, compared to FONR's ROE of +0.04%. Regarding short-term risk, MASS is more volatile compared to FONR. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check FONR's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, LUCD has a market cap of 111M. Regarding current trading prices, MASS is priced at $6.74, while LUCD trades at $1.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas LUCD's P/E ratio is -1.57. In terms of profitability, MASS's ROE is +0.13%, compared to LUCD's ROE of -5.91%. Regarding short-term risk, MASS is more volatile compared to LUCD. This indicates potentially higher risk in terms of short-term price fluctuations for MASS.Check LUCD's competition here

MASS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 251.9M. In comparison, RCEL has a market cap of 110.8M. Regarding current trading prices, MASS is priced at $6.74, while RCEL trades at $4.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -7.33, whereas RCEL's P/E ratio is -2.69. In terms of profitability, MASS's ROE is +0.13%, compared to RCEL's ROE of +4.77%. Regarding short-term risk, MASS is less volatile compared to RCEL. This indicates potentially lower risk in terms of short-term price fluctuations for MASS.Check RCEL's competition here